Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review.

[1]  A. Smyth,et al.  Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  A. Gaggar,et al.  Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial. , 2019, The American journal of clinical nutrition.

[3]  G. Santyr,et al.  Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease. , 2019, Academic radiology.

[4]  J. Emerson,et al.  Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0-11years. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  A. Smyth,et al.  P251 How does the current clinical trials landscape reflect the James Lind Alliance top ten research priorities for CF? , 2018, Journal of Cystic Fibrosis.

[6]  Alicia J. French,et al.  Procalcitonin, erythrocyte sedimentation rate and C‐reactive protein in acute pulmonary exacerbations of cystic fibrosis , 2018, The clinical respiratory journal.

[7]  L. Saiman,et al.  Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. , 2018, Diagnostic microbiology and infectious disease.

[8]  S. Stanojevic,et al.  Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis , 2018, Thorax.

[9]  W. Morgan,et al.  Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations , 2017, Annals of the American Thoracic Society.

[10]  D. Nicolau,et al.  Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency , 2017, Respiratory medicine case reports.

[11]  D. Sanders,et al.  Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  D. Sanders,et al.  Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  D. Sanders,et al.  Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[14]  E. Nash,et al.  The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers , 2017, Thorax.

[15]  Shuzhao Li,et al.  Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D3 administration. , 2017, Metabolism: clinical and experimental.

[16]  C. Werner,et al.  Chest physiotherapy can affect the lung clearance index in cystic fibrosis patients , 2017, Pediatric pulmonology.

[17]  P. Hodgkins,et al.  Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States , 2017, Current medical research and opinion.

[18]  H. Elphick,et al.  Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[19]  C. Schwarz,et al.  Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis , 2016, BMJ Case Reports.

[20]  Kurt A. Wargo,et al.  Successful Use of Ceftolozane‐Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug‐Resistant Pseudomonas aeruginosa , 2016, Pharmacotherapy.

[21]  M. Wildman,et al.  Duration of intravenous antibiotic therapy in people with cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[22]  Hans-Ulrich Kauczor,et al.  Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis , 2016, American journal of respiratory and critical care medicine.

[23]  V. Waters,et al.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[24]  T. Remmington,et al.  Oral anti-pseudomonal antibiotics for cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[25]  S. Stanojevic,et al.  Physiologic endpoints for clinical studies for cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[26]  M. Botteman,et al.  Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis , 2016, Health and Quality of Life Outcomes.

[27]  A. Horsley,et al.  Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. , 2016, The Cochrane database of systematic reviews.

[28]  M. Elkins,et al.  A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis , 2016, Thorax.

[29]  A. Balaguer,et al.  Home versus hospital intravenous antibiotic therapy for cystic fibrosis. , 2015, The Cochrane database of systematic reviews.

[30]  S. Stanojevic,et al.  Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[31]  P. Flume,et al.  Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. , 2015, The Cochrane database of systematic reviews.

[32]  S. Heltshe,et al.  Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. , 2015, Annals of the American Thoracic Society.

[33]  T. Willgoss,et al.  Understanding the Suitability of Cystic Fibrosis-Specific Clinical Outcome Assessments For Clinical Trials and to Support Medical Product Labeling , 2015 .

[34]  D. Sanders,et al.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis , 2015, Thorax.

[35]  M. Wilschanski,et al.  Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[36]  H. Selvadurai,et al.  A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation , 2014, European Respiratory Journal.

[37]  Al-AloulMohamed,et al.  Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. , 2014 .

[38]  M. Rybak,et al.  Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient. , 2014, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[39]  C. Terwee,et al.  Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a ‘core outcome set’ , 2014, Trials.

[40]  K. McCoy,et al.  Osteopathic Manipulative Treatment for Inpatients With Pulmonary Exacerbations of Cystic Fibrosis: Effects on Spirometry Findings and Patient Assessments of Breathing, Anxiety, and Pain , 2014, The Journal of the American Osteopathic Association.

[41]  H. Kauczor,et al.  Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. , 2014, American journal of respiratory and critical care medicine.

[42]  D. Sin,et al.  Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. , 2013, Chest.

[43]  K. Stiller,et al.  Physical activity levels of patients with cystic fibrosis hospitalised with an acute respiratory exacerbation. , 2013, Respiratory medicine.

[44]  S. Stick,et al.  Novel end points for clinical trials in young children with cystic fibrosis , 2013, Expert review of respiratory medicine.

[45]  T. Remmington,et al.  Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. , 2013, Paediatric respiratory reviews.

[46]  D. Hansell,et al.  Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation , 2013, Thorax.

[47]  H. Duivenvoorden,et al.  Impact of bronchiectasis and trapped air on quality of life and exacerbations in cystic fibrosis , 2013, European Respiratory Journal.

[48]  Marleen de Bruijne,et al.  Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation. , 2012, American journal of respiratory and critical care medicine.

[49]  B. Stanton,et al.  Iron Homeostasis during Cystic Fibrosis Pulmonary Exacerbation , 2012, Clinical and translational science.

[50]  R. Lyles,et al.  Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation , 2012, European Journal of Clinical Nutrition.

[51]  F. Cameron,et al.  Glucose Tolerance during Pulmonary Exacerbations in Children with Cystic Fibrosis , 2011, PloS one.

[52]  J. Carlin,et al.  Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. , 2011, JAMA.

[53]  R. Fischer,et al.  Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. , 2011, American journal of respiratory and critical care medicine.

[54]  E. Baraldi,et al.  Endpoints in respiratory diseases , 2011, European Journal of Clinical Pharmacology.

[55]  M. O'riordan,et al.  Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations , 2010, Respiratory research.

[56]  D. Seder,et al.  Piperacillin-Induced Immune Hemolytic Anemia in an Adult with Cystic Fibrosis , 2010, Case reports in medicine.

[57]  M. Hodson,et al.  Short-term comparative study of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis , 2009, Thorax.

[58]  P. Watter,et al.  Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions. , 2009, Child: care, health and development.

[59]  C. Cracowski,et al.  Continuous versus Intermittent Infusions of Ceftazidime for Treating Exacerbation of Cystic Fibrosis , 2009, Antimicrobial Agents and Chemotherapy.

[60]  A. Quittner,et al.  Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. , 2009, Chest.

[61]  D. Reinhardt,et al.  Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[62]  C. Goss,et al.  Patient-reported outcomes in cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.

[63]  M. Rosenfeld,et al.  Endpoints for clinical trials in young children with cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.

[64]  B. Yankaskas,et al.  Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[65]  J. Elborn,et al.  Clinical trials in cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[66]  B. Assael,et al.  Chest physiotherapy with positive airway pressure: a pilot study of short-term effects on sputum clearance in patients with cystic fibrosis and severe airway obstruction. , 2006, Respiratory care.

[67]  I. Abdulhamid,et al.  Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis , 2006, Pediatric pulmonology.

[68]  G. Hafen,et al.  Clinical scoring systems in cystic fibrosis , 2006, Pediatric pulmonology.

[69]  P. Ohtake,et al.  Physiologic evidence for high-frequency chest wall oscillation and positive expiratory pressure breathing in hospitalized subjects with cystic fibrosis. , 2005, Physical therapy.

[70]  L. Saiman,et al.  The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. , 2005, Chest.

[71]  P. Bye,et al.  Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial , 2005, The Lancet.

[72]  P. Watter,et al.  Respiratory exacerbations in children with cystic fibrosis: Physiotherapy treatment outcomes , 2005, Physiotherapy theory and practice.

[73]  V. Lucidi,et al.  Resting energy expenditure in young patients with cystic fibrosis receiving antibiotic therapy for acute respiratory exacerbations. , 2002, Clinical nutrition.

[74]  P. Baghurst,et al.  Efficacy of once‐daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: A preliminary study * , 2001, Pediatric pulmonology.

[75]  Bowerman,et al.  Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis , 2000, European journal of clinical investigation.

[76]  D. Orenstein,et al.  Comparison of flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation , 1999, Pediatric pulmonology.

[77]  J. Kanga,et al.  Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. , 1999, Clinical therapeutics.

[78]  G. Redding,et al.  Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis , 1999 .

[79]  F. Kelly,et al.  Treatment of pulmonary exacerbations of cystic fibrosis leads to improved antioxidant status. , 1999, The European respiratory journal.

[80]  D. Homnick,et al.  Comparison of the flutter device to standard chest physiotherapy in hospitalized patients with cystic fibrosis: a pilot study. , 1998, Chest.

[81]  D. Schidlow,et al.  Pulmonary function in hospitalized infants and toddlers with cystic fibrosis. , 1998, The Journal of pediatrics.

[82]  L. Breysem,et al.  Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. , 1998, The Journal of antimicrobial chemotherapy.

[83]  V. Stallings,et al.  Acute pulmonary exacerbation is not associated with increased energy expenditure in children with cystic fibrosis. , 1998, The Journal of pediatrics.

[84]  S. Conway,et al.  Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. , 1997, Thorax.

[85]  D. Nielson,et al.  Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis , 1997, Pediatric pulmonology.

[86]  F. Gottrand,et al.  Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis , 1997, Archives of disease in childhood.

[87]  D. Turck,et al.  Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients , 1996, European Journal of Pediatrics.

[88]  C. Delacourt,et al.  Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[89]  L. Zanolla,et al.  Short‐term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: A cross‐over randomized study , 1995, Pediatric pulmonology.

[90]  M. Newport,et al.  Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. , 1994, The European respiratory journal.

[91]  M. Hodson,et al.  Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. , 1992, The European respiratory journal.

[92]  E. Valletta,et al.  Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis , 1992, Acta paediatrica.

[93]  J. A. Cooper,et al.  Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients. , 1991, The Pediatric infectious disease journal.

[94]  M. Zach,et al.  Chest physiotherapy in hospitalized patients with cystic fibrosis: a study of lung function effects and sputum production. , 1991, The European respiratory journal.

[95]  W. Warwick,et al.  Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. , 1990, The American review of respiratory disease.

[96]  R. Kraemer,et al.  Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin , 1989, European Journal of Clinical Microbiology and Infectious Diseases.

[97]  R. Cowan,et al.  Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. , 1989, The Journal of pediatrics.

[98]  L. Ward,et al.  Short-term nutritional supplementation during management of pulmonary exacerbations in cystic fibrosis: a controlled study, including effects of protein turnover. , 1988, The American journal of clinical nutrition.

[99]  J. Bosso,et al.  Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. , 1988, The Pediatric infectious disease journal.

[100]  H. Auerbach,et al.  Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. , 1987, The Journal of pediatrics.

[101]  A. Giunta,et al.  Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. , 1987, The Pediatric infectious disease journal.

[102]  J. Bosso,et al.  Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. , 1987, The American journal of medicine.

[103]  R. Stern,et al.  Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. , 1987, The American journal of medicine.

[104]  M. Jackson,et al.  Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. , 1986, Pediatric infectious disease.

[105]  R. Kraemer,et al.  Antimicrobial Therapy of Pseudomonas Pulmonary Exacerbations in Cystic Fibrosis , 1986, Acta paediatrica Scandinavica.

[106]  A. Prince,et al.  Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. , 1985, Reviews of infectious diseases.

[107]  A. Olinsky,et al.  The role of piperacillin therapy in pulmonary exacerbations of cystic fibrosis: A controlled study , 1985, Pediatric pulmonology.

[108]  B. Joos,et al.  Ciprofloxacin-induced hematuria , 1985, Infection.

[109]  R. Stern,et al.  Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis. , 1985, Reviews of infectious diseases.

[110]  J. Ledbetter,et al.  Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis. , 1985, The Journal of pediatrics.

[111]  C. Buchanan,et al.  Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. , 1984, Reviews of infectious diseases.

[112]  J. van der Laag,et al.  Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. , 1983, The Journal of antimicrobial chemotherapy.

[113]  H. Levison,et al.  Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis , 1983, Pediatric infectious disease.

[114]  E. Mellits,et al.  A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. , 1981, The Journal of pediatrics.

[115]  G. Mccracken,et al.  Acute Pulmonary Exacerbations in Cystic Fibrosis A Double-blind Trial of Tobramycin and Placebo Therapy , 1980 .

[116]  C. Anderson,et al.  Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis. , 1980, Archives of disease in childhood.

[117]  R. Kraemer,et al.  RELATIVE UNDERWEIGHT IN CYSTIC FIBROSIS AND ITS PROGNOSTIC VALUE , 1978, Acta paediatrica Scandinavica.

[118]  J. Davies,et al.  Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[119]  Draft Guidance.  Multiple Endpoints in Clinical Trials Guidance for Industry , 2017 .

[120]  V. Waters,et al.  Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. , 2015, The Cochrane database of systematic reviews.

[121]  I. Abdulhamid,et al.  Hepatotoxicity induced by trimethoprim-sulfamethoxazole in a child with cystic fibrosis. , 2014, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[122]  M. Walshaw,et al.  Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[123]  C. Wainwright,et al.  Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. , 2013, The Cochrane database of systematic reviews.

[124]  A. Smyth,et al.  Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2012, The Cochrane database of systematic reviews.

[125]  A. Horsley,et al.  Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. , 2012, The Cochrane database of systematic reviews.

[126]  V. Waters,et al.  Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. , 2020, The Cochrane database of systematic reviews.

[127]  M. Hodson,et al.  Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[128]  D. Bilton,et al.  Evaluation of Once Daily Tobramycin Versus the Traditional Three Time Daily for the Treatment of Acute Pulmonary Exacerbations in Adult Cystic Fibrosis Patients , 2006 .

[129]  J. Elborn,et al.  A comparison of pulmonary exacerbations with single and multiple organisms in patients with cystic fibrosis and chronic Burkholderia cepacia infection. , 2003, The Journal of infection.

[130]  R. Echols,et al.  Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. , 1997, The Pediatric infectious disease journal.

[131]  K. De Boeck,et al.  Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: Preliminary communication , 1989, Pediatric pulmonology.

[132]  B. Strandvik,et al.  Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. , 1989, Scandinavian journal of infectious diseases. Supplementum.

[133]  J. Blumer,et al.  Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis , 1988, Pediatric pulmonology.

[134]  M. Corey,et al.  A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. , 1988, Journal of clinical epidemiology.

[135]  D. Goldmann,et al.  Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis. , 1983, The Journal of antimicrobial chemotherapy.